| Company Name: |
Daicel Chiral Technologies (China)CO.,LTD
|
| Tel: |
021-50460086-9 15921403865 |
| Email: |
han_yajun@dctc.daicel.com |
| Products Intro: |
Product Name:Edoxaban-D6
CAS:1304701-57-2
Purity:95%HPLC Package:10MG;25MG;50MG;100MG Remarks:DCTI-A-219
|
| Company Name: |
Artis Biotech Co. Ltd.
|
| Tel: |
18208119189 13890853691 |
| Email: |
sales@artisbio.com |
| Products Intro: |
Product Name:Edoxaban-d6
CAS:1304701-57-2
Purity:98%HPLC Package:1mg;5mg;10mg;50mg
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:[2H6]-Edoxaban
CAS:1304701-57-2
Purity:CP:95%; 98%atom Package:5mg Remarks:B71433
|
Edoxaban-d6 manufacturers
- Edoxaban-D6
-
- $1630.00
-
2026-05-11
- CAS:1304701-57-2
- Purity:
- Supply Ability: 10g
|
| | Edoxaban-d6 Basic information |
| Product Name: | Edoxaban-d6 | | Synonyms: | Edoxaban-d6;N-[(1S,2R,4S)-4-[bis(trideuteriomethyl)carbamoyl]-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]-N'-(5-chloropyridin-2-yl)oxamide;[2H6]-Edoxaban;Edoxaban hydrochloride salt;2H6]-Edoxaban hydrochloride salt;D6-Edoxaban | | CAS: | 1304701-57-2 | | MF: | C24H30ClN7O4S | | MW: | 548.06 | | EINECS: | | | Product Categories: | | | Mol File: | 1304701-57-2.mol |  |
| | Edoxaban-d6 Chemical Properties |
| Melting point | >205°C (dec.) | | storage temp. | Hygroscopic, Refrigerator, under inert atmosphere | | solubility | Chloroform (Slightly), Dichloromethane (Slightly) | | form | Solid | | color | Pale Orange to Pale Red | | Stability: | Hygroscopic |
| | Edoxaban-d6 Usage And Synthesis |
| Description | Edoxaban-d6 is intended for use as an internal standard for the quantification of edoxaban by GC- or LC-MS. Edoxaban is an orally bioavailable and potent inhibitor of factor Xa (Kis = 0.561 and 0.903 nM for free and complexed human factor Xa, respectively). It is >10,000-fold selective for factor Xa over thrombin, FVIIa/sTF, FXIa, tPA, aPC, trypsin, plasmin, and chymotrypsin. Edoxaban prolongs prothrombin, activated partial thromboplastin, and thrombin clotting times in a concentration-dependent manner ex vivo in human plasma. Oral administration of edoxaban (0.5-12.5 mg/kg) reduces thrombus formation and prolongs prothrombin time in a dose-dependent manner in rat and rabbit models of venous stasis thrombosis. It also reduces thrombus formation in a rat model of platinum wire-induced venous thrombosis. Formulations containing edoxaban have been used to prevent stroke in patients with atrial fibrillation. | | Uses | Edoxaban-d6 is the isotope labelled analog of Edoxaban (E555520); an anticoagulant drug which acts as a direct factor Xa inhibitor. | | References | [1] T. FURUGOHRI. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles[J]. Journal of Thrombosis and Haemostasis, 2008, 6 9: 1542-1549. DOI: 10.1111/j.1538-7836.2008.03064.x |
| | Edoxaban-d6 Preparation Products And Raw materials |
|